RED BANK, N.J., Feb. 18, 2021 /PRNewswire/ -- Provention
Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to
intercepting and preventing immune-mediated disease, today
announced that it will report its fourth quarter and full year 2020
financial results on February 25,
2021 before the opening of the U.S. financial markets.
Subsequently, at 8:00 am E.T., the
company will host a conference call to discuss its financial
results and provide a corporate update.
To access the call, please dial 1-877-870-4263 (domestic) or
1-412-317-0790 (international) ten minutes prior to the start
time and ask to be connected to the "Provention Bio Call." An audio
webcast will also be available on the "Events and Webcasts" page of
the Investors section of the Company's website,
www.proventionbio.com. An archived webcast will be available
on the Company's website approximately two hours after the
conference call.
SVB Leerink Global Healthcare Conference
Additionally, the company announced it will participate in a
fireside chat presentation at the 2021 SVB Leerink Global
Healthcare Conference on Thursday, February
25, 2021, at 1:40 pm E.T.
A webcast of the presentation can be accessed by visiting the
Events and Webcasts section of the Company's
website: http://investors.proventionbio.com/events. The
webcast will be archived on the Company's website for 30 days
following the presentation.
About Provention Bio, Inc.:
Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical
company focused on advancing the development of investigational
therapies that may intercept and prevent debilitating and
life-threatening immune-mediated disease. The Biologics License
Application (BLA) for teplizumab, its lead investigational drug
candidate, for the delay or prevention of clinical type 1 diabetes
in at-risk individuals, has been filed by the U.S. Food and Drug
Administration (FDA). The Company's pipeline includes additional
clinical-stage product candidates that have demonstrated in
pre-clinical or clinical studies proof-of-mechanism and/or
proof-of-concept in other autoimmune diseases, including celiac
disease and lupus. Visit www.ProventionBio.com for more
information and follow us on Twitter: @ProventionBio.
Internet Posting of Information:
Provention Bio, Inc. uses its
website, www.proventionbio.com, as a means of disclosing
material nonpublic information and for complying with its
disclosure obligations under Regulation FD. Such disclosures will
be included on the Company's website in the "News" section.
Accordingly, investors should monitor this portion of the Company's
website, in addition to following its press
releases, SEC filings and public conference calls and
webcasts.
Investor Contacts:
Robert
Doody, VP of Investor Relations
rdoody@proventionbio.com
484-639-7235
Sam Martin, Argot Partners
sam@argotpartners.com
212-600-1902
Media Contact:
Lori Rosen, LDR Communications
lori@ldrcommunications.com
917-553-6808
View original content to download
multimedia:http://www.prnewswire.com/news-releases/provention-bio-to-report-fourth-quarter-and-full-year-2020-financial-results-on-february-25-2021-301230700.html
SOURCE Provention Bio, Inc.